Antineoplastics (ALK inhibitors)
- Target oncogenic ALK signaling
- Major use: ALK-positive NSCLC
- Alectinib/lorlatinib are key modern agents
- CNS penetration is clinically important
- Bradycardia, edema + hepatic AEs vary
- Lorlatinib: lipids + neuropsychiatric effects
- Resistance mutation pattern can guide sequencing
Class at a glance
- Target oncogenic ALK signaling
Members / distinctions
- Alectinib/lorlatinib are key modern agents
- Lorlatinib: lipids + neuropsychiatric effects
Clinical role
- Major use: ALK-positive NSCLC
- CNS penetration is clinically important
- Resistance mutation pattern can guide sequencing
Practical pearls
- Bradycardia, edema + hepatic AEs vary
Drugs in this class (4)
All drug classes · Open the interactive console ↗
